Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ)

Shares of Verve Therapeutics (NASDAQ:VERV) climbed for the second straight session on Tuesday after Cantor Fitzgerald upgraded the stock based on early-stage trial data the gene editing company posted for its cholesterol therapy VERVE-102.

Verve (NASDAQ:VERV) closed 26% higher on